A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Summary

The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS). This study is a long-term extension of study J6I-MC-OWAA (NCT07100119) and is part of the OLMP (NCT07571200) master protocol that will last approximately 96 weeks.

Timeline

Start

2026-05-14

Primary completion

2029-06

Completion

2029-06

Drugs

Indications